Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

260 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-01

Study Completion Date

2025-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, randomized, double-blind, placebo-controlled, phase II-III clinical trial to evaluate the efficacy and safety of the study drug in adult patients with pulmonary arterial hypertension (PAH).

The trial will evaluate the efficacy and safety of both single and multi-dose (seven-day) administrations of the study drug in three dosages: 0.03 mg/kg, 0.10 mg/kg, and 0.17 mg/kg.

The trial is an observer-blinded trial, since the appearance of the study drug and Placebo differs from each other. Patients included in the trial, as well as trial coordinators, investigators, and study center staff will be blinded. The only unblinded staff in the study centers will be those who preparing IP/Placebo and administering IP/Placebo to the study patients.

The trial will include 200 patients with PAH, who will be sequentially included in the trial in two stages.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)

NCT00993408

Pulmonary Arterial Hypertension

COMPLETED PHASE2

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

NCT00323024

Pulmonary Hypertension

WITHDRAWN PHASE2

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

NCT04266197

Pulmonary Arterial Hypertension

COMPLETED PHASE2

Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension

NCT03057028

Pulmonary Arterial Hypertension

COMPLETED PHASE1

Repurposing Valsartan May Protect Against Pulmonary Hypertension

NCT06053580

Pulmonary Arterial Hypertension Right Heart Failure Right Ventricular Dysfunction +1 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Lyophilisate for solution for intravenous administration, 6.3 mg

Intervention Type DRUG

Placebo

0.9% sodium chloride

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of PAH II or III functional class according to WHO classification
* Symptomatic PAH group 1 according to clinical classification
* Patients who have not previously received any PAH-specific therapy OR patients who have received endothelin receptor antagonists and/or iloprost/selexipag at stable doses for at least 3 months prior to the initial right heart catheterization.
* Ability to perform reproducible 6-min walking test at the screening with a distance from 150 to 450 m.